Explore drug efficacy or safety with unprecedented relevance and de-risk your asset with our advanced high-throughput screening platforms. Our scalable assays enable screening of extensive compound libraries, accelerating lead identification and optimizing your drug discovery pipeline.
How it works
Our platform enables flexible scaling with single organoid precision. Coupled with state-of-the art analytical technologies, BrainZell’s organoid platform is especially suitable for early drug discovery research in target identification, phenotypic screening, lead optimization, neurosafety and translational research.
Our platform is designed to handle large volumes of experiments simultaneously, drastically reducing turnaround times and accelerating your path to actionable results.
Explore early, how repeated exposures mirroring clinical treatment regimes affect the outcomes. Uncover lasting efficacy and potential resistance and refine dosing strategies for optimal patient outcomes.
Unlock a new level of accuracy by focusing on each organoid individually. Our advanced technology ensures that every organoid’s unique characteristics are captured and measured, delivering precise data you can trust for robust and reproducible results.
Our models offer possibility for microglia co-culture, enabling the discovery of the neuroimmune aspects of disease progression and treatment response.
Capture dynamic, real-time responses through live assays, monitor treatment effects and biomarkers using liquid biopsies, and preserve crucial structural details in fixed organoid assays. Our multi-faceted approach provides a holistic view of your experimental outcomes.
Customized hiPSCs Sourcing
Choose what works best for you application
a diverse range of genetic backgrounds from established biobanks.
collaborating with clinical partners to obtain patient-specific cells.
utilize your own iPSC lines for personalized applications.
Assay Ready
Our platform enables single exposure to long term treatment possibilities
Tests per week
Organoids